An analysis of a meta-analysis encompassing five RCTs with 1,091 GBM patients-1,034 in the experimental group and 867 in the control group-found that adding anti-vascular endothelial growth factor to standard therapy significantly improved PFS compared to standard therapy alone (OR 0.76, 95% CI 0.65–0.89; high-quality evidence, Class IV) (Figure 4) [48]. The gene discussed is VEGFA; the disease is glioblastoma.